Please enable JavaScript or talk to your local administrator to get JavaScript enabled.
Skip filters
Skip facets
Funder
  • 15

  • 7

  • 4

  • 4

  • 4

  • 3

  • 2

  • 2

  • 1

  • 1

Funder Group
Research Organization
FOR (ANZSRC) Category
RCDC Category
Researcher
City
State
Country
Country of Funder
Start Year
Active Year
Similar Projects for

Project

PFI-TT: The Development of Flow-Through Sensors for the Detection of Bladder Cancer in Urine Samples

Funder: Directorate for Engineering

Funding period
USD 249 K
Funding amount
Abstract
The broader impact/commercial potential of this Partnerships for Innovation - Technology Translation (PFI-TT) project concerns the benefits of non-invasively detecting cancer in small samples of accessible bodily fluids (blood, urine, saliva). All biofluids are abundantly populated with small sacs that express specific indicators (biomarkers) when cancer is present. The ability to sample biofluids and detect these indicators is the basis of the "liquid biopsy" concept. A liquid biopsy for blood could be incorporated into routine laboratory tests and catch cancer in its earliest stages where intervention is most impactful. A liquid biopsy in urine could be used to replace highly invasive procedures currently used to routinely surveil for recurrence of bladder cancer. This PFI-TT project seeks to hasten the arrival of routine cancer screening through liquid biopsy by fundamentally advancing the way biosensors are used in these assays to make them faster and more sensitive. Educationally, the project will train two talented post-graduate scientists in the key elements of technical entrepreneurship. The project will also maintain several opportunities for undergraduates to conduct academic research including programs supporting under-represented groups and individuals unlikely to otherwise be exposed to research in college. The proposed project will advance the concept of the liquid biopsy by developing flow-through sensors that detect cancer biomarkers on extracellular vesicles (EVs) in urine. Current biomarker detection schemes require the analyte to diffuse from the sample to the sensing surface, resulting in slow and often incomplete, responses. The project will emphasis a different paradigm where the sensor is built on a highly permeable membrane and EVs carrying the biomarkers pass through the membrane where they are captured and revealed through enzyme-based detection. The team will develop and optimize the chemistries for capture of biomarkers and development of signal on the ultrathin silicon nitride membranes with precision slit-pores. The team will also develop mathematical models of flow through slit-pore membranes and the EV capture process. Finally, the team will compare our experiments and models to results with diffusion-limited sensors. This will directly test the hypothesis that the flow-through configuration enables more sensitive and faster responding devices that can improve detection of cancer in liquid biopsies. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

 
50
Projects
USD 45.0 M
Aggregated funding amount
USD 978 K
Average funding amount
Project list item
Novel Biomarkers for the Clinical Management of Bladder Cancer

National Cancer Institute to VINATA B LOKESHWAR

USD 466,211
2018 - 2023
Project list item
Circulating tumor DNA as a predictive biomarker in metastatic bladder cancer

Canadian Institutes of Health Research to Gillian Rae Vandekerkhove, Alexander William Wyatt

USD 53,221
2018 - 2021
Project list item
Non invasive Cell Based Liquid Biopsy Platform for Bladder Cancer

European Commission

USD 4,291,985
2017 - 2020
Project list item
Improved detection of bladder cancer recurrence using a biophysical biomarker

National Cancer Institute to MICHAEL D HENRY

USD 299,860
2017 - 2019
Project list item
IGF::OT::IGF GENETIC CYTOLOGY FOR SURVEILLANCE OF RECURRENT BLADDER CANCER

National Cancer Institute to ISAAC KINDE

USD 1,915,127
2017 - 2019
Project list item
Translation of a Clinical Molecular Diagnostic Assay for Bladder Cancer

National Cancer Institute to STEVE GOODISON

USD 1,238,725
2017 - 2022
Project list item
GENETIC CYTOLOGY FOR SURVEILLANCE OF RECURRENT BLADDER CANCER

National Institutes of Health to ISAAC KINDE

USD 1,915,127
2016 - 2017
Project list item
IGF::OT::IGF GENETIC CYTOLOGY FOR SURVEILLANCE OF RECURRENT BLADDER CANCER

National Cancer Institute to ISAAC KINDE

USD 299,824
2016 - 2017
Project list item
Monitoring Recurrent Bladder Cancer with Electro-Phage Biosensors

National Cancer Institute to GREGORY A. WEISS

USD 932,247
2016 - 2019
Project list item
Precision Medicine in Platinum-Treated Lethal Bladder Cancer

Congressionally Directed Medical Research Programs to Jonathan Rosenberg

USD 788,605
2015 - 2016
Project list item
Precision Medicine in Platinum-Treated Lethal Bladder Cancer

Congressionally Directed Medical Research Programs to David Mcconkey

USD 411,266
2015 - 2016
Project list item
Precision Medicine in Platinum-Treated Lethal Bladder Cancer

Congressionally Directed Medical Research Programs to Eliezer M Van allen

USD 346,210
2015 - 2016
Project list item
Circulating Tumor Cell-Based Patient-Derived Xenograft Models of Metastatic Bladder Cancer as a Platform for Development of Novel Therapeutic Approaches

Congressionally Directed Medical Research Programs to Matthew Galsky

USD 673,356
2015 - 2016
Project list item
Stratification of patients with bladder cancer for cystoscopic surveillance

Innovate UK to Helen Mill

USD 756,850
2015 - 2017
Project list item
Development of the UroMark assay. A non-invasive test for the detection of bladder cancer in urinary sediment cells

Medical Research Council to John Kelly, Martin Anyim, Norman R Williams, Chris Brew-Graves, Stephan Beck, Andrew Feber

USD 2,167,155
2015 - 2019
load more...